At the postreceptor level, MR activation could synergize with downstream pathways, which may be activated concomitantly by other signaling mechanisms leading to amplification of the MR-mediated signaling.
Importantly, while the expression/activity of the MR is mandatory for adequate Na balance, the physiological role of MR in the CV system is unclear. None of the cell-specific MR gene inactivation models (nor MRA treatment in basal condition) revealed a clear phenotype in the absence of a second stressor (hormone infusion, salt administration, metabolic stress, cardiac, or vascular injury, etc.) suggesting that MR expressed in these cell types is involved in pathophysiological conditions only.
MR ANTAGONISTS
Much of the research that has demonstrated the role of MRs in CV diseases is based on the use of pharmacological MRAs. These antagonists have a beneficial effect in various animal models of disease as well as in several clinical trials. Two MRAs are currently used in humans: spironolactone and eplerenone. Both have similar therapeutic benefit but different pharmacological characteristics.
Spironolactone is a first-generation MRA, which has been used clinically for decades. The RALES study demonstrated the beneficial effects of adding spironolactone to standard therapy (ACE inhibitor and furosemide diuretic) in patients with severe HF, reducing mortality, and morbidity. 4 From a pharmacological point of view, spironolactone has a very strong antagonistic effect on MRs but is relatively nonspecific. It also binds to other steroid receptors, such as androgen and progesterone receptors, and causes endocrinal side effects (gynecomastia, impotence, etc.). 15 Eplerenone is a second-generation MRA. It has greater selectivity for the MR than spironolactone, which limits undesirable side effects. However, it has lower affinity than spironolactone (approximately 40-fold less), requiring higher doses to achieve the same effects. 15 The clinical benefits of eplerenone on mortality and morbidity have been demonstrated in the clinical studies EPHESUS, in patients with left ventricular dysfunction after MI, 5 and EMPHASIS, in patients with systolic HF and mild symptoms. 6 MR activation in the distal nephron leads to sodium reabsorption, as well as potassium excretion. The use of MRAs can therefore lead to potassium retention and hyperkaliemia, a potentially dangerous side effect that can lead to cardiac arrhythmias, especially in patients with impaired renal function. The use of these antagonists thus requires careful patient selection and regular monitoring of kalemia and renal function. Of note, a recent meta-analysis showed that only half of the hyperkaliemia reported in randomized clinical trials (RCTs) using MRAs was indeed related to the MRA treatment, while 46% was related to other reasons. 16 Despite the risk of hyperkalemia, MRAs are beneficial even in HF patients with impaired renal function. 17 Furthermore, hypokalemia is associated with worse outcomes in HF patients receiving optimal therapy but without MR blockade. The correction of hypokalemia indeed amplifies the beneficial effects of eplerenone. 18 Nonsteroidal MRAs have been developed to circumvent the side effects of steroidal MRAs. 19 Some of them such as finerenone are currently in the clinical trial phase and are reported to have better specificity and efficacy than spironolactone and eplerenone. 15, 20 The results obtained with finerenone in phase II clinical trials are encouraging. In patients with HF with reduced ejection fraction and moderate chronic kidney disease, finerenone 5-10 mg/day was at least as effective as spironolactone 25 or 50 mg/day in decreasing biomarkers of hemodynamic stress, but it was associated with lower incidences of hyperkalemia. 21 The use of finerenone in patients with worsening HF with reduced ejection fraction and chronic kidney disease and/or diabetes mellitus induced a ≥30% decrease in plasma N-terminal pro-B-type natriuretic peptide levels in a similar proportion of patients to eplerenone. 22 Furthermore, patients in the finerenone 10-20 mg dose group had the largest reduction in the composite outcome of death from any cause, CV hospitalization compared with patients in the eplerenone group. 22 Of note, only a modest blood pressure reduction was noticed in these 2 trials. Phase III clinical trials will be required to validate these results over a longer duration on larger patient populations. 23 One RCT is indeed ongoing to assess the effect of finerenone in patients with diabetic nephropathy on the occurrence of CV outcomes (FIGARO: NCT02545049).
ROLE OF MR IN CV DISEASES

Mineralocorticoid receptor and heart failure
The involvement of MR in CV pathophysiology was first demonstrated in animal models subjected to mineralocorticoid overload with infusion of Aldo or deoxycorticosterone acetate (DOCA) combined with a high-salt diet, often associated to unilateral nephrectomy (NephrectomyAldosterone-Salt). These experimental models associate hypertension, cardiac hypertrophy, and the development of ventricular fibrosis, revealing the harmful CV impact of MR activation. These adverse effects are prevented by pharmacological MRAs. 23, 24 Subsequently, several studies have shown that involvement of MR in cardiac pathophysiology is not limited to models of mineralocorticoid overload. In animals, pharmacological MR blockage limits the transition to HF in left ventricular dysfunction 3 and MI models, 25 as well as diastolic dysfunction models in rats 26 and mice. 27 The RALES, 4 EPHESUS, 5 and EMPHASIS 6 studies clearly demonstrated the beneficial effects of pharmacological MR blockade in patients with moderate-to-severe HF, suggesting that excessive activation of MR is involved in the pathophysiology of HF. More recently, the TOPCAT study evaluated this benefit in HF patients with preserved ejection fraction. 28 Initial results of the study reported no significant beneficial effect of spironolactone on mortality or hospitalization for HF. 28 However, there was a large geographical disparity in the results, and post-hoc analysis revealed a benefit of spironolactone in patients living on the American continent. 29 Dahal et al. 30 recently performed a meta-analysis analyzing the impact of MRAs in RCTs including patients with ejection fraction greater than 40% or without congestive HF and conclude that treatment with MRAs is associated with a mortality benefit in patients with ST-elevation MI with LVEF greater than 40% or without HF. Coronary artery disease is a leading cause of HF. Spironolactone improved coronary microvascular function (as indicated by the coronary reserve) in patients with type 2 diabetes. 31 Similar benefits have been reported for eplerenone after only 4 weeks of treatment. 32 Some RCTs are ongoing to assess the impact of MRAs in atherosclerosis (NCT02169089) or vascular function in type 2 diabetes (NCT03017703). Restenosis poststenting has also been targeted but with negative result in a small clinical trial. 33 
MR and electrophysiological disorders
Numerous studies also reported the involvement of the MR in cardiac electrophysiological disorders. Ex vivo, Aldo induces an increase in T-type calcium channel activity in cultured rat cardiomyocytes, leading to an increase in the frequency of their beats. 34 In vivo, Aldo infusion or MR overexpression in cardiomyocytes induces cardiac ion channel remodeling, which has important consequences on the control of calcium homeostasis, and leads to cardiac arrhythmias. 35 MRAs have shown beneficial electrophysiological effects in murine models of tachycardia, 36 aortic constriction, 37 arrhythmia, 38 atrial fibrillation (AF), 39 hypertension, 40 and mineralocorticoid challenge. 41 In clinical studies, the risk of AF is greater in hypertensive patients with primary hyperaldosteronism than those without. 42 In addition, serum aldosterone levels are elevated in patients with chronic AF and decrease rapidly after electrical cardioversion. 43 Patients with AF also show higher expression levels of MR 44 and 11HSD2 45 in atrial cardiomyocytes. MRAs have shown beneficial effects in dialysis patients 46 or those who have undergone cardiac surgery, 47 with a reduction in the occurrence of AF. They also reduce AF-related hospitalizations in patients with AF. 48 The MRAs reduce the risk of rhythm disorders and cardiac arrest in patients with HF 49 or after MI. 50 Beneficial effects of pharmacological MR blockade with eplerenone have been demonstrated in patients with acute ST-elevation MI without HF (REMINDER trial) with a reduction in biological markers such as lower BNP/NT-proBNP l 51 or procollagen type III N-terminal propeptide 52 serum levels. The ALBATROSS trial aimed to study the impact of early MR blockade (single intravenous bolus of potassium canrenoate) in acute MI but failed to show a benefit of early MRA use in addition to standard therapy in patients admitted for MI. 53 However, a prespecified meta-analysis of patient-level data of patients with STEMI included in the REMINDER and ALBATROSS RCTs concluded that MRA treatment is associated with a reduction of death and death or resuscitated sudden death. 54 
MR and vascular disorders
Pharmacological blockade of the MR by spironolactone or eplerenone has beneficial effects on vascular reactivity. Numerous studies with animal models showed beneficial effects of MRA on the endothelial dysfunction associated with diabetes, 55 high-fat diet, 56 and myocardial infarct. 57 In rats treated with Aldo, eplerenone prevents the increase in blood pressure and reduces vascular rigidity. 58 The role of MR-mediated upregulation of a specific long variant of the L-type Ca v 1.2 Ca channel in heart and vessels has been recently explored, 59 as well as mineralocorticoid-dependent regulation of the microRNA-155 which targets the Ca v 1.2 L-type calcium channel and promotes vasoconstriction and blood pressure increase with aging. 60 The epithelial Na channel ENaC, a well-known aldosterone target in the distal nephron that controls Na balance, may also participate to the mineralocorticoid-dependent regulation of vascular tone and properties: Vascular ENaC expression is increased in the vasculature by aging and high-fat diet as well as aldosterone. 61, 62 MR is also involved in atherosclerosis and vascular remodeling associated with local injury, as reviewed recently by DuPont and Jaffe 63 and Lother and Hein. 64 Steroidal MRAs are efficient to prevent atherosclerosis or neointima formation after injury in animal model. 63, 64 In recent study, finerenone significantly reduced apoptosis of endothelial cells and attenuated vascular smooth muscle proliferation in a mouse model of vascular injury, thus improving vascular healing and preventing adverse vascular remodeling. 65 In clinical trials, MRAs improved endothelial function in hypertensive patients 66 and had a positive nondiuretic effect on blood pressure 67 and vascular remodeling 68 in patients with end-stage renal failure. Changes in serum miR-155 predicted the blood pressure treatment response in elderly subjects treated with MRA suggesting the clinical relevance of the modulation of Ca v 1.2 L-type calcium channel by miR-155.
Cell-specific role of the MR in CV diseases
The beneficial effects of MRAs highlight the importance of MR activation in CV pathophysiology. However, this pharmacological approach does not distinguish between the involvement of the MR expressed in different cell types. In the heart, the MR is expressed by various cell types including cardiomyocytes, vascular smooth muscle cells, endothelial cells, fibroblasts, and macrophages. 69 The pathological implication of the MR in these different cell types has been studied using models with tissue-specific MR invalidation or overexpression in mice.
Genetic inactivation of MR in cardiomyocytes reduced pathological remodeling in the DOCA-salt model 70 and in a model of MI, 71 as well as cardiac function in an aortic constriction model. 72 Invalidation of the MR in fibroblasts had no effect in the same aortic constriction model. 72 Mice with MR inactivation in vascular smooth muscle cells have lower blood pressure and lower vascular stiffness than control mice during aging 73 or after an Aldo-salt challenge 74 and show improvement in left ventricular dysfunction after MI. 25 MR invalidation in endothelial cells protects mice against DOCA-induced cardiac remodeling and inflammation. 75 In addition, endothelial cell MRs are involved in diet-induced oxidative stress and inflammation, leading to diastolic dysfunction, cardiac fibrosis, and aortic stiffness. 76 Sex differences in vascular response to cardiometabolic risk factors have been evidenced. Female but not male mice are sensitive to obesity-induced endothelial dysfunction. 77 Davel et al. 77 recently identified the endothelial MR as a key actor in the sex dimorphism related to obesity-induced microvascular dysfunction, suggesting that gender should be considered to assess the potential benefit of MRAs in obese patients that may be present in female obeses but not in males. Furthermore, the proatherogenic effects of aldosterone were recently shown to be mediated by an increase in ICAM-1 expression induced by endothelial MR activation in a mouse model of atherosclerosis. 78 The cross-talk between adipose tissue and the vascular wall is essential and may account for the impact of metabolic disease and obesity on CV function. The activation of MR expressed by adipocytes plays a role in the local production of hydrogen peroxide, leading to remote effects on the vasculature leading to impaired vascular contractility. 79 The role of MRs expressed by immune cells has also been studied and will be discussed later.
PATHOPHYSIOLOGICAL MECHANISMS OF MR ACTIVATION
The pathophysiological mechanisms involved in the deleterious effects of MR activation are complex and diverse. However, 3 processes have been clearly identified: oxidative stress, inflammation, and fibrosis.
MR and oxidative stress
During the metabolism of oxygen, reactive oxygen species (ROS) are generated: superoxide anion (O2 •− ), hydrogen peroxide, and hydroxyl radicals (HO • ). These ROS are highly reactive and can cause tissue damage when their levels are not properly regulated. Under physiological conditions, they are eliminated as they are produced and do not represent a danger to the organism. However, excessive production disrupts the balance between formation and elimination, resulting in oxidative stress. ROS then react abnormally with the biological components of tissues and lead to pathological situations. 80 Several studies have shown that oxidative stress is an important mechanism responsible for the effects of Aldo and MR activation. 81 Indeed, the Aldo/MR complex positively regulates the expression of NADPH oxidase subunits, an oxygen-reducing enzyme that is responsible for the production of ROS, 81 thus inducing an increase in oxidative stress (Figure 1) .
The consequences of oxidative stress are many and contribute to the pathological effects of MR activation. Oxidative stress induces DNA damage 82 and can lead to posttranslational changes (carbonylation, sulfenic acid modification) of important signaling pathways involved in the onset of disease. 27, 83 In addition, oxidative stress is involved in activation of the NF-κB signaling pathway, which plays an important role in mediating inflammation and fibrosis. 81 In vitro, Aldo can stimulate the production of ROS by rat cardiomyocytes. 84 In addition, MRAs prevent the development of oxidative stress in animal models of CV disease. 3, 57 Spironolactone reduced cardiac oxidative stress status and prevented cardiac damage in a rat model of streptozotocin-induced diabetes. 85 It has also been shown that oxidative stress can activate MR signaling in rat cardiomyocytes, via the action of the Rac1 protein, even in the absence of ligand, 13 suggesting an MR activity amplification loop mediated by oxidative stress (Figure 1 ). Cardiac overexpression of constitutively activated Rac1 promotes MR activation and cardiac fibrosis. 86 The involvement of Rac1 in the activation of MR was described in a chronic pressure overload mouse model of HF: Rac1 activation increased the expression of MR and MR target genes in the heart. 87 Both these effects were reversed by systemic MR blockade, pharmacological Rac1 inhibition, and genetic deletion of Rac1 in cardiomyocytes. 87 In clinical studies, the implication of MR activation in oxidative stress production has been suggested by the reduction in oxidative stress markers upon MRA treatment in kidney transplantation or adrenalectomy in patients with primary aldosteronism: Spironolactone decreased urinary hydrogen peroxide levels after living donor kidney transplantation, 88 while adrenalectomy decreased urinary isoprostane levels in PA patients. 89 
MR and inflammation
After tissue damage, the release of pro-inflammatory cytokines by the damaged cells leads to the recruitment of cells of the innate immune system to the site of injury. This initial inflammation, involving primarily macrophages and neutrophils, participates in the removal of dead cells and the first phase of tissue repair. However, when such inflammation becomes chronic, it leads to activation of cells of the adaptive immune system and contributes to the development of various mechanisms involved in CV pathologies, such as hypertension and fibrosis. 90, 91 The major role of inflammation in the development of CV disease is now clearly established. 90, 92 Inflammatory markers are associated with poor clinical prognosis and patients with hypertension and CV disease present chronic vascular inflammation. 91 Activation of MRs contributes to the maintenance of inflammation, 93 including activation of the NF-κB pathway and induction of pro-inflammatory cytokine expression (IL-6, TNF-α, IFN-γ, etc.) 94 (Figure 1) . Pharmacological blockade of MR reduces the chronic inflammation associated with CV dysfunction. 95 It prevents the cardiac inflammation induced in models of left ventricular dysfunction 3 and mineralocorticoid overload. 96 These data suggest that the MR can amplify the immune mechanisms that play a critical role in initiating and maintaining hypertension, CV remodeling, and target organ damage.
Furthermore, MRs are expressed by cells of the immune system and can modulate their function. Activation of MRs induces polarization of macrophages toward a pro-inflammatory M1 phenotype (Figure 1) , whereas MR gene invalidation in macrophages leads to an anti-inflammatory M2 phenotype. 97, 98 Genetic invalidation of the MR in myeloid cells (macrophages, dendritic cells, and neutrophils) prevents the development of atherosclerosis in mice 99 and inflammation and cardiac fibrosis in many pro-fibrotic models such as DOCA-salt challenge, 100 abdominal aortic constriction, 101 and treatment with hypertensive molecules, such as L-nitro-arginine methyl ester (L-NAME) 69, 98 or angiotensin II. 98 In addition to its role in innate immunity, MRs expressed by adaptive immune cells, T lymphocytes, in particular, have been shown to also be involved in hypertension and CV remodeling. 102, 103 T lymphocytes are adaptive immune cells that carry out a specific immune response when activated by antigen-presenting cells, such as dendritic cells or macrophages. Cytotoxic CD8 + T cells act directly by eliminating certain target cells (damaged, infected, cancerous, or those presenting not-self-markers), whereas CD4 + T cells act as modulators of the immune response. CD4 + T cells can be T helper cells (Th), which promote and amplify the immune response, or T regulatory cells (T-regs), which inhibit it. Two subtypes of Th cells have a highly pro-inflammatory phenotype and are associated with chronic inflammation and CV diseases: Th1 cells (source of IFN-γ) and Th17 cells (source of IL-17, IL-21, and IL-22). 94 In animals, the DOCA-salt challenge induces T-cell polarization to a pro-inflammatory Th1/Th17 phenotype, via activation of the MRs expressed by dendritic cells 95 ( Figure 1 ). In addition, the protective effect of MRAs Figure 1 . MR activation by aldosterone (A) or glucocorticoids (G) (when 11β-hydroxysteroid dehydrogenase type 2-11HSD2-is not active) induces the expression of NADPH oxidase (NOX). NOX activity results in the production of reactive oxygen species (ROS), highly reactive molecules that generate oxidative stress. Oxidative stress contributes to activation of the NF-κB pathway, which in turn leads to inflammation and fibrosis. Oxidative stress also activates MR signaling through the action of the Rac1 protein. MR activation by aldosterone induces the expression of pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ), as well as ROS production and NF-κB pathway activation. MR activation is also involved in the polarization of macrophages (Mφ) and T cells toward the pro-inflammatory phenotypes M1 and Th17, respectively. These effects all contribute to amplify inflammation, which in turn promotes fibrosis. MR activation by aldosterone induces the expression of pro-fibrotic molecules (ET1, TGF-β, PAI-1, CTGF, fibronectin, and collagen I, III, and IV) and promotes inflammation, which participates in the activation of myofibroblasts, cells that produce high quantities of ECM components. These effects lead to the accumulation of ECM components in the extracellular space, resulting in fibrosis. Abbreviations: CTGF, connective tissue growth factor; ECM, extracellular matrix; MR, mineralocorticoid receptor.
against DOCA-salt challenge-induced CV remodeling is associated with inhibition of T-cell polarization toward a Th17 phenotype. 95, 104 A recent study using a constriction model of the abdominal aorta also showed that invalidation of the MR in T cells protects the heart of mice from dysfunction, hypertrophy, fibrosis, and inflammation. 103 In vitro, invalidation of the MR in T cells decreased their activation, whereas it was increased by overexpression of the MR, revealing a direct role for MRs expressed by T cells in their activation. 103 There is also a growing body of evidence describing the role of immune cells in hypertension, 85 and a recent study has highlighted the involvement of MRs expressed by T cells in this mechanism, via the regulation of IFN-γ. 102 After treatment with angiotensin II, mice in which the MR gene was inactivated in their T cells were protected against hypertension, tissue damage, and accumulation of INF-γ producing cells (CD8 + T cells, in particular) in the kidney and aorta. 102 Conversely, mice overexpressing the MR in their T cells showed even greater hypertension than WT mice, and this difference was reversed by treatment with anti-IFN-γ antibodies. 102 In vitro, invalidation of the MR in cultured CD8 + T cells induced a decrease in INF-γ expression, whereas MR overexpression or Aldo treatment of CD8 + T cells induced an increase in INF-γ expression. 102 
MR and fibrosis
Fibrosis is a major pathophysiological mechanism of many chronic inflammatory conditions. It is characterized by excessive production and accumulation of extracellular matrix components, such as collagen and fibronectin, in damaged or inflamed tissue. This mechanism can lead to organ dysfunction because differentiated and specialized cells of the organ are replaced by fibrous scar tissue that is unable to fulfill the specific roles necessary for proper organ function. Chronic hypertension, for example, is accompanied by cardiac hypertrophy due, in part, to abnormal accumulation of extracellular matrix components in the extracellular space. Fibrosis increases myocardial rigidity, which contributes to ventricular dysfunction and can lead to HF. 105 Chronic MR activation is associated with extracellular matrix remodeling, cell growth, and fibrosis, mechanisms that contribute to the development of CV diseases. 24, 106, 107 Aldo alone (ex vivo), or in combination with salt (in vivo), stimulates the expression of many pro-inflammatory and pro-fibrotic molecules that contribute to the pathophysiology of cardiac remodeling: endothelin 1, transforming growth factor β, plasminogen activator inhibitor-1, connective tissue growth factor, fibronectin, and collagen types I, III, and IV 7, 108, 109 (Figure 1) .
Chronic administration of mineralocorticoid hormones (Aldo or DOCA) and salt in uninephrectomized rats induces perivascular and interstitial cardiac fibrosis. These effects are independent of the increase in blood pressure because blocking MR prevents cardiac fibrosis, even at nonhypotensive doses. 110 The development of fibrosis appears to begin around the vessels (associated with coronary and myocardial inflammation) and then spreads to the cardiac interstitium. 109 In models of MI, scarring and fibrosis are reduced by pharmacological blockade of the MR 111 or genetic inactivation of the MR in mouse cardiomyocytes. 71 Administration of salt, in addition to Aldo or mineralocorticoids, appears to be a prerequisite for induction of cardiac fibrosis in vivo in rodent experimental models. Cardiac overexpression of Aldo synthase 112 or MR 35 or increased plasma Aldo levels alone 113 are not sufficient to induce cardiac fibrosis in mice. This suggests that cofactors (salt in particular) are necessary for the pro-fibrotic effects of Aldo in vivo. However, a recent study described the development of mild cardiac fibrosis in mice subjected to a very high dose of Aldo alone. 114 The beneficial effects of eplerenone in the EPHESUS clinical study were associated with reduced plasma levels of the fibrosis marker, procollagen type I amino-terminal propeptide (PINP). 115 Plasma levels of this marker in stroke patients are also reduced by spironolactone treatment. 116 In addition to its role in cardiac fibrosis, MR is also involved in the fibrosis of other organs, such as the kidney, 117 liver, 118 lungs, 119 and skin. 120 The pro-fibrotic role of the MR thus appears to be a general pathophysiological mechanism linked to its activation.
CONCLUSION AND PERSPECTIVES
In conclusion, an ever-growing amount of experimental and clinical evidence shows the involvement of inappropriate MR activation in the pathophysiology of CV diseases. The clinical benefits obtained from the use of new nonsteroidal MRAs are encouraging, paving the way for the wider use of MRAs in patients, even with associated renal dysfunction. The pathological mechanisms involved by MR activation are complex, ranging from oxidative stress to fibrosis and inflammation. Inflammation is of particular importance, given its central role in the pathophysiology of CV diseases. 121 Furthermore, new targets of the MR in the CV system have been identified in recent years, such as neutrophil gelatinase-associated lipocalin, 122 galectin-3, 114 and cardiotrophin-1, 123 allowing a better understanding of the pathways involved in the pathophysiology of MR activation. These molecules have been shown to play important roles in Aldo-induced cardiac fibrosis and inflammation 114, 123, 124 and may represent new therapeutic targets in CV diseases.
